Group 1 - The core viewpoint of the news is that Sunflower has experienced a significant stock price fluctuation, with a year-to-date increase of 122.22% but a recent decline of 5.26% over the last five trading days [1] - As of November 19, Sunflower's stock price is 7.20 CNY per share, with a market capitalization of 9.268 billion CNY and a trading volume of 172 million CNY [1] - The company has seen a net outflow of main funds amounting to 16.5384 million CNY, with large orders showing a buy of 27.0751 million CNY and a sell of 41.7075 million CNY [1] Group 2 - Sunflower's main business focuses on the pharmaceutical sector, particularly in the research, production, and sales of drugs for anti-infection, cardiovascular, and digestive system treatments [1] - The revenue composition of Sunflower includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other non-main businesses [1] - As of September 30, the number of shareholders has increased to 133,000, a rise of 112.98%, while the average circulating shares per person have decreased by 53.05% [2] Group 3 - Sunflower has distributed a total of 204 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]
向日葵跌2.04%,成交额1.72亿元,主力资金净流出1653.84万元